| Literature DB >> 25176652 |
Nathiya Muthalagu1, Melissa R Junttila2, Katrin E Wiese3, Elmar Wolf3, Jennifer Morton1, Barbara Bauer3, Gerard I Evan2, Martin Eilers3, Daniel J Murphy4.
Abstract
MYC is one of the most frequently overexpressed oncogenes in human cancer, and even modestly deregulated MYC can initiate ectopic proliferation in many postmitotic cell types in vivo. Sensitization of cells to apoptosis limits MYC's oncogenic potential. However, the mechanism through which MYC induces apoptosis is controversial. Some studies implicate p19ARF-mediated stabilization of p53, followed by induction of proapoptotic BH3 proteins NOXA and PUMA, whereas others argue for direct regulation of BH3 proteins, especially BIM. Here, we use a single experimental system to systematically evaluate the roles of p19ARF and BIM during MYC-induced apoptosis, in vitro, in vivo, and in combination with a widely used chemotherapeutic, doxorubicin. We find a common specific requirement for BIM during MYC-induced apoptosis in multiple settings, which does not extend to the p53-responsive BH3 family member PUMA, and find no evidence of a role for p19ARF during MYC-induced apoptosis in the tissues examined.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25176652 PMCID: PMC4231288 DOI: 10.1016/j.celrep.2014.07.057
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423